Puget Sound Business Journal: CounterX Therapeutics inks licensing deal for opioid abuse treatments
PRESS RELEASE CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose SEATTLE ...
CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose
PRESS RELEASE CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose SEATTLE ...
CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders
PRESS RELEASE CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders SEATTLE, WA – (February 26, 2026) CounterX Therapeutic ...
Wired: A Fentanyl Vaccine Is About to Get its First Major Test
PRESS RELEASE CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose SEATTLE ...
CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model
PRESS RELEASE CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model SEA ...